Open access peer-reviewed chapter

Application of Lead Transport through Brain Capillary for Determination of Weight, Brain Damage, and Encephalization Quotient in Humans

Written By

Saganuwan Alhaji Saganuwan

Submitted: 03 June 2022 Reviewed: 29 August 2022 Published: 10 October 2022

DOI: 10.5772/intechopen.107459

From the Edited Volume

The Toxicity of Environmental Pollutants

Edited by Daniel Junqueira Dorta and Danielle Palma de Oliveira

Chapter metrics overview

68 Chapter Downloads

View Full Metrics

Abstract

The ability of lead to cause brain damage and reduce intelligence quotient has been established. However, transport of lead through brain capillary has not been elucidated. Hence, plasma and brain tissue kinetics of lead was studied mathematically. Literatures were searched for formulas that could be used for the determination of relationship between plasma and brain tissue kinetics of lead with an interest to discovering the residence time of lead residues in brain. Findings have shown that 5μg/dl of lead in plasma permeates the brain of human weighing 20 kg faster than that of 40 kg and 70 kg body weight, respectively. The surface area of permeability of brain cell is higher, in low body weight human than in high body weight human. Time of exposure and concentration of lead are higher in low body weight human as compared to high body weight human. Hence, neonates and children are more vulnerable to brain damage than adult human.

Keywords

  • encephalopathy
  • lead
  • brain capillary
  • toxicokinetics
  • encephalization quotient
  • transport

1. Introduction

Plasma concentration (>5 to >100 μg/dl) of lead can cause neurological, cardiovascular, hematological, reproductive, renal, immunological, and respiratory problems [1]. The reported lead concentrations of surface sample of soil was 23–35 mg/kg soil, whereas the concentration of the lead elute from soil was 0.6 mg/L, respectively [2]. Lead has the ability to penetrate brain having molecular weight of 207.28 g [3] and elimination half-life of 18 months. Highly contaminated soil could have the concentration of lead 3.03 times higher than the maximum limit for agricultural soil and 1.97 times higher than the value limit for fodder [4], suggesting that lead is very stable in soil and toxic to human [5]. However, soil concentration of lead (11.42 mg/L) could decrease during rainy season relative to dry season [6]. Lead exerts opposite effects on antibody response and phagocytosis [7]. Some plants such as Cyamopsis tetragonoloba and Sesamum indicum could tolerate lead concentration of up to 1000 mg/kg; hence, they could be used for bioremediation of soil heavily contaminated by lead [8]. The factors responsible for penetration of central nervous system acting agents are lipid solubility, pH, and molecular weight [9]. Hence, toxicological study of chemicals is necessary for the identification of potential toxicants [10]. Severe lead poisoning in young children and neonatal rats may cross microvessel endothelium of the brain. There is evidence that lead can cause brain damage, and lead uptake in the endothelium is reduced by calcium adenosine triphosphatase (ATPase) pump [11]. In view of this, transport of lead through brain capillary was mathematically assessed with a view to identifying pathogenesis of brain injury caused by lead in humans.

Advertisement

2. Materials and methods

2.1 Calculation of blood and plasma lead concentration

Literatures were assessed with a view to obtaining formulas that could be used for the calculation of lead transport through brain capillaries and its pathogenesis of causing brain damage and low intelligence quotient. Measurement of red blood cell (RBC) partitioning of lead is done as follows:

Plasma Imax,ufupPlasma Imax+Fa×Fg×Ka×DoseQhRbE1

where Imax=Cmaxμmol,Doseμmol,fup= fraction of unbound drug in plasma (lower limit, 0.01), Ka= absorption rate constant (0.1 min1), Fa= fraction absorbed (1), Fg= fraction escaping gut metabolism (1), Qh= hepatic blood flow (1.6 L/min), and Rb= blood–plasma concentration ratio [12].

Distribution of lead toredblood cells%=1Plasma conc×100HCBlood conc×100×100E2
Blood to plasma ratio=Blood ConcPlasma ConcE3
Hb=PVCrCl×D×Scr×72K×140Age×12.5×10.33E4
D=PcrScr×144.E5
RDB=RRW×80ml1kg×DesiredPCVRecipientPCVDonorPCVE6

2.2 Blood and tissue kinetics of lead

Cl=DRCssE7
LD=Css×VdE8

The first-order equation that describes the release of lead from biological system is concentration-dependent and can be expressed as [13]:

logCt=logCoKt2.303E9

where Co= initial concentration of lead and Ct= concentration of lead in solution at time t. slope equals K2.303 [14]. The elimination rate constant (1.16 h−1) terminal half-life (0.6 h−1) and volume of distribution (1.03 L/kg) have been reported for 60 kg weighted man.

Hence, terminal half-life

t12β=VdPCl×0.693E10

where PCl = plasma clearance. However, initial concentration (Co) is calculated as:

Co=DVappE11

where D = dose of lead; Vapp = apparent volume of distribution, when renal function is not impaired the serum concentration:

Cs=observed concentration0.2xAlbuming/dl+0.1E12

When there is end-stage renal failure, the serum concentration is calculated as:

Cs=observed concentration0.1xAlbuming/dl+0.1E13

Integration of exposure time with toxic dose of lead is presented as:

D=TnKE14

where D = dose, T = time of exposure, and K = concentration of toxicant causing toxicity [15].

2.3 Translation of lead dose in animals to human

HED=Animal dose×KmHumanKmE15

Animal dose and animal Km are substituted with 40 and 20 kg as well as 31.3 and 25.0, respectively [16].

2.4 Transport of lead through brain capillary

Lead can be transported through brain capillary having the rate constant:

Kin=QEVbrainE16
E=1ePSAQE17
AlternativelyEr=CinCoutCinE18

where Q = brain capillary blood flow, E = fraction of lead that flow into the brain, Vbrain = volume of brain, Er = extraction ratio of lead, PSA = permeability surface area (MS1m2 of blood-brain barier, Cin = concentration of lead entering the brain capillary molL1, and Cout = concentration of lead leaving the brain capillary [17, 18].

The passive flux (QPas) of lead across blood-brain barrier between plasma and the brain extracellular fluid (ECF) is given as:

QPas=PCplCECFE19

where QPas = passive flow rate molm2s1, P = permeability of the BBB MS1, Cpl=concentration of the lead in the plasma molm3, and CECF= concentration of lead in the ECF [19]:

CECFt=kBBBCplCECFE20
VECF=ECFt=CLBBBCplCECFE21
CECF=AECFVECFE22

Cerebral metabolic rate (CMR) scales with brain volume, hence:

CMRV=αV0.167E23
Density of neuronDn=αV0.167E24
The capillary length densityCn=αV0.167E25

Total length of capillary is proportional to the number of neurons [20].

Capillary diameterCd=αV0.08E26

It is 7μmdiameter in human brain [21]. The flow rate of blood to the brain is 800mL/min [22]where CECF = change in lead concentration of extracellular fluid, KBBB = rate constant of lead transport across the BBB (S1), CL BBB = transfer clearance of lead transport across the BBB m3S1, AECF = molar amount of lead in the brain ECF mol, and VECF= volume of the brain ECF m3 [23, 24, 25].

Passive permeabilityp=Ptrans+DparaWTJE27

where Pt = passive transcellular permeability ms1,Dpara = diffusity of lead through the BBB intercellular space m2s1, and WTJ = width of tight junction (m) [24].

Total fluxQtotal=PtotCplCECFE28
Qtotal=PAFinCplPAFoutCECFE29

where Ptotal = rate of active and passive transport across BBB, PAFin = affinity of lead to active transport into the brain, and PAFout = affinity of lead to active transport out of the brain [25].

Ptot=Ppas×CpartE30

Ppas = passive permeability to BBB; Cpart= coefficient of partition [26].

Active clearanceClact=TmKm+CE31

where Tm = maximum rate of lead transport across the BBB (μmolL1S1, Km = concentration of free lead μmolL1 at which half of Tm is attained, and C = concentration of lead in plasma [27].

Change in lead concentration within the cells of the brain is given as follows:

CICFt=KcellCECFCICFE32
VICFCICFt=CcellCECFCICFE33
CICFAICFVICFE34

where CICF = concentration of lead in the brain ICF μmolL1, Kcell= rate constant of lead transport across the cell membrane S1, and VICF= apparent volume of distribution in the brain ICF [28].

Dissociation constantkd=konkoffE35

where kd=45.62nM0.91μg/dL that has been reported for on-site lead detection using a biosensor device [29].

2.5 Michaelis-Menten kinetics of lead

Clearance of lead by Michaelis-Menten kinetics is given as follows:

CLactcell=TmcellKmcell+CE36

where CLactcell = active transfer clearance of free lead across the cell membrane, C = concentration of lead in the brain ECF or ICF, Tmcell= maximal veolocity of the transporter, and Kmcell= Michaelis –Menten constant [30].

Enzyme metabolic clearance φmet is given as follows:

φmet=VmaxCKm+CE37

where φmet = flux of the enzymatic metabolic reaction mmolL1min1, Vmax = maximum flux of the reaction mmolL1, C = concentration of substrate in ECF or ICF (mmolL1, and Km = affinity of coefficient of the enzyme substrate mmolL1 [31]. Three-dimensional model that integrates lead transport through BBB and lead binding within the brain could predict lead distribution in the brain [32]. One kilogram equals 1000 mililiters [33].

2.6 Relationship between brain mass and encephalization quotient

Encephalization quotientEQ=Brain mass0.14×Body weight0.528E38
Brain massE=kpβE39

where k = 0.14, p = body weight, and β = 0.528 [34, 35].

Brain volumelog10B=3.015+0.986log10CE40

where B = brain size (mm3) and C = internal cranial capacity (mm3).

Also brain volumeVbrain=43×π×r3E41

where

π=3.14159andr=radius=diammeter2E42
T12β=0.693βE43

Lead concentration (Ct), plasma clearance (Pcl), calculated administered lead and time of exposure to lead were extrapolated to 60, 40, and 20 kg weighed human, using human equivalent dose formula.

2.7 Parameters for the determination of therapeutic and toxic agents across brain cells

The relevant parameters that can be used for the determination of therapeutic and toxic agents across brain cells are as follows: capillary radius (3–5 ×106m), capillary surface area (15–25m2), intercapillary distance (40–60 ×106m), capillary blood flow rate (0.3–200 × 101Lmin1), BBB passive permeability 6×108106ms1, BBB rate constant (1.4 × 1041.4×102S1), BBB transfer clearance 113850×105LS1, BBB trancellular permeability 0.610×107ms1, BBB paracellular diffusity 550767×1012m2s1, width tight junction 0.30.5×106m, active transport velocity 22167μmolL1S1, concentration to reach half of Tm4.55×103μmolL1, BBB surface area 1218167m2, blood cebrospinal fluid barrier (BCSFB) surface area 69m2, cerebrospinal fluid (CSF) flow rate 5067×107LS1, brain ECF flow velocity 28×107ms1, brain ECF volume fraction (0.23–0.49), tortuosity (1.5–1.7), effective diffusion constant 0.115×1010m2s1, cellular uptake rate 0.22304.3s1, cellular transfer clearance 4.2×1033×105LS1, ICF volume (960 L), association rate constant 2.8×1052.8×102μmolL1S1, binding site concentration 1×1035×101μmolL1, affinity constant 0.003528×103μmolL1, maximum reaction flux 5.76×1021×109μmolL1min1, and elimination rate constant 1.1×1076.8×104S1 have been reported for human brain [12].

Advertisement

3. Results

Table 1 shows kinetic parameters of lead in various compartments of brain of 20, 40, and 60 kg weighted adult humans.

ParametersValue
Weight (kg)604020
Volume of brain (mm3)440030001500
Fraction of blood flowed into the brain (μg/dl)5.05.05.0
Rate constant of brain transport through capillary (kin) (L/min)3.4 × 10−4 to 2.3 × 10−15 × 10−4 to 3.3 × 10−11.0 × 10−3 to 6.7 × 10−1
Permeability surface area (m2)0.0640.251.13
Concentration at time (Ct) (mol/s)1.872.242.81
Plasma clearance (Pcl) (L/S)1.191.431.78
Dose of administered lead CD5.156.177.73
Time of exposure (T) (h)5.206.237.80
Brain diameter (mm)20.417.914.2
Brain radius (mm)10.28.97.1
Brain elimination half-life (S−1)6.3 × 10−8–1.0 × 10−36.3 × 10−8–1.0 × 10−36.3 × 10−8–1.0 × 10−3
Blood lead level (μg/dl)0.52–8.38131–7.292.1–6.2
Blood-to-plasma ratio0.1–1.70.3–1.50.4–1.2
Erythrocytes lead level (μg/dl)3.382.291.2
Brain mass (kg)4.43.01.5
Encephalization quotient3.63.12.2

Table 1.

Kinetic parameters of lead in the brain of humans of varying weights.

Advertisement

4. Discussion

The increased rate constant of lead transport through brain capillary, permeability surface area, concentration of lead in the brain, and time of exposure to lead in 20 kg weighed human as compared to 40 and 60 kg weighed humans agree with the report of Nicholson [35] indicating that young humans are more vulnerable to plumbism. The increased plasma clearance of lead in the human of 20 kg body weight as compared to 40 and 60 kg body weight human agrees with the report indicating that children have the ability to eliminate lead faster than adult [35]. Absorption of lead by bone and teeth is 94% in adult as compared to 70% in children [36]. Half-life of blood lead is 40 days in human. Renal insufficiency caused by plumbism could delay lead elimination. Lead concentration lower than 5 μg/dL is associated with reduced academic performance. Tyrosine and phenylalaine are the two main binding sites in albumin. The binding site is Tyr84 and Cys34 [37]. The allowable lead limit in drinking water is 15Ppb73nM [38, 39]. Serum albumin consists of 585 amino acids which have three structural domains stabilized in disulfide bonds with binding sites for fatty acids, glycerol, and metal ions. The ability of lead to bind serum albumin is used to detect micromolar concentration of lead ions in biological solution [40, 41, 42]. Centre for disease control’s (CDC’s) limit of 5 μg/dl in blood is contrary to revised limit of 3.5 μg/dl, but even 3 μg/dl has caused diminished cognitive function [43]. Protein kinases regulate the development of brain capillaries and expression of blood-brain barrier. Lead could stimulate protein kinase, disrupting BBB development at the regulation of neuronal development. More so, low doses of lead can stimulate protein kinase C that may enhance the release of neurotransmitters [44]. Protein kinase C is most sensitive to lead followed by calmodulin-protein kinase C and cyclic adenosine monosphosphate protein kinase [45]. Toxic action of lead is influenced by the interaction between endothelial cells and astrocytes [46]. Genetic and environmental factors could make some particular children more vulnerable to lead neurotoxicity [47]. Human brain is made up of 100 billion neurons, which consumes 15–20 W power. Brain consumes 15–20% of consumed glucose [48]. Utilization of adenosine triphosphate (ATP) in gray matter and white matter are 9.5 μmolg1S1 and 3 μmolg1S1, respectively, signifying that 77% energy is consumed by cortical gray matter, which is 50% of brain volume. Components of gray matter are dendrites, neurons, glial cells, unmyelinated axons, and capillaries, but components of white matter are glial cells, myelinated axons, and capillaries. The density of brain capillary is 2–4 times more in gray matter [49]. Adult human brain weighs 1500 g and occupies 1200 cm3, with surface area of microvessels (100–200 cm2g1) [50]. Brain extracellular space constitutes 15–30% of the brain volume and brain vasculature 3% of the brain volume [51]. Increased size of human brain from 400 cm3 to 1200 cm3 [52] indicates increased cognition capacity of modern human. Serum creatinine0.88±0.2mg/dl has been reported for human with blood lead level of 2.362.54μg/dl [53]. Blood level of 24.43±5.31μg/dl has been reported for traffic policeman in Taiwan [54]. Less than 1.5 min cerebral perfusion of labeled lead chloride was fast, providing a space of 9.7 mol/100 g of frontal cortex at 1 min. The influx was linear with concentration of 4 μM. Albumin (5%), cistern (200 Mm), and ethylene diamine tetraacetate (EDTA) (1 μm) slipped lead uptake. Potassium reduces lead 203 uptakes [55]. Concentration of lead in blood 2.16.2μg/dl has been reported for children [56] and 0.52–8.38 μg/dl in adults [57]. Brain weight of man decreases by 2.7 g and that of human by 2.2 g per year with increasing age. Also brain weight increase of 3.7 g is independent of sex [58]. However brain weight increased by 0.78 g/year for 80 years between 1860 and 1940, amounting to 62.4 g [59]. Cognitive ability is dependent on number of neurons [60]. White matter decreases in old (75–85 years) as compared to young by 11% [61]. Hence, there is a need to revise the toxic reference value of lead in children. The reference value of 3.5 μg/dl should be revised to guide clinical and public intervention for individual children [62], because the relationship between encephalization and intelligence could be affected by low allometric value, when linear regression line was used [63]. Brain size, different regions of the brain including cerebral cortex, cortical thickness, frontal cortex, parietal cortex, cerebellum, and experience correlated positively with intelligence. Therefore, gene and environmental influence plays a key role in intelligence quotient [64], as such brain size based on cognitive equivalence is preferred to the encephalization quotient in empirical cognitive studies [65]. Environment could affect the development of neural tissues [66].

Advertisement

5. Conclusion

Lead fragments permeate blood–brain barrier of a young human weighing 20 kg body weight faster than those of humans weighing 40 and 60 kg body weights. However, rate constant of brain transport, permeability surface area, lead concentration in the brain, and exposure time of lead are higher in children leading to low encephalization quotient.

Advertisement

Abbreviations

Hbhaemoglobin
PVplasma volume
Ddepuration
Scrserum creatinine
Kconstant
Pcrplasma creatinine
RDBrequired donor blood
RRWrecipient real weight
PCVpacked cell volume
Clclearance
DRdose rate
Csssteady state concentration
LDloading dose
Vdvolume of distribution
HEDhuman equivalent dose
Kmmetabolism consant
Kinrate constant of lead transport through brain capillary
VECFextracellular fluid volume
αflow rate of blood to the brain
AICFmolar amount of lead in intracellular fluid
Kondissociated lead
Kofforiginal lead
βelimination rate constant of lead

References

  1. 1. Hayes AW. Principles and Methods of Toxicology. 5th ed. Boca Raton, FL: CRC Press; 2008. p. 2270
  2. 2. Thi LanBinh N, Hoang NT, Thi Thanih Truc N, Khang VD, Anh Le H. Estimating the possibility of lead contamination in soil surface due to lead deposition in atmosphere. Journal of Nanomaterials. 2021;2021:ID5586951
  3. 3. Winecker RE, Rofero-Miller JD, Broussard LA, Hammett-Stabler CA. The toxicology of heavy metalal: Getting the lead out. Laboratory Medicine. 2002;33:934
  4. 4. Castro-Bedrinana J, Chirinos-Peinado D, Garcia-Olarte E, Quispe-Ramos R. Lead transfer in the soil-root-plant system in a highly contaminated Andean area. Peer Journal. 2021;2021:10624
  5. 5. Lima FDS, Nascimento CND, da Silva FBV, de Carvalho VGB, Fillio MRR. Lead concentration and allocation in vegetable crops grown in a soil contaminated by battery residues. Horticultura Brasileira. 2009;29(3):362-365
  6. 6. Obasi PN, Akudinobi BB. Potential health risk and levels of heavy metals in water resources of lead-zinc communities of Abakaliki, Southeast Nigeria. Applied Water Research. 2020;10(184):1-23
  7. 7. Laschi-Loquerie A, Eyraud A, Morisset D, Samai A, Tachon P, Veysscyre C, et al. Influence of heavy metals on the resistance of mice toward infection. Immunopharmacology and Immunotoxicology. 1987;9(2&3):235-241
  8. 8. Amin H, Arain BA, Jahangor TM, Abbasi MS, Amin F. Accumulation and distribution of lead (pb) in plant tissues to guar (Cyamopsis tetragonolosis L) and sesame (Sesamum indiaim L.): Profitable phytoremediation with biofuel crops. Geological Ecology Landscape. 2018;2(1):51-60
  9. 9. Saganuwan SA. Piroxicam: Source for synthesis of central nervous system (cns) acting drugs. Central Nervous Agent Medicine Chemistry. 2017;17:1-6
  10. 10. Saganuwan SA. Toxicity studies of drugs and chemicals in animals: An overview. Bork Journal of Veterinary Medicine. 2016;10:983
  11. 11. Bradbury NW, Deane R. Permeability of the blood-brain barrier to lead. Neurotoxicology. 1993;14(2-3):131-136
  12. 12. Saganuwan SA. In: Erkekogh P, Ogawa T, editors. Toxicosis of snake, scorpion, honeybees, spider, and wasp venoms: Part 2, Medical Toxicology. Hund: Intech Open; 2021. p. 335
  13. 13. Saganuwan SA. Application of modified Michaclis-Menten equations for determination of enzyme inducing and inhibiting drugs. BMC Pharmacology and Toxicology. 2021;22(57):1-15
  14. 14. Suvakanta D, Nhurthy PN, Lilakanta N, Prasanta C. Kinetic modeling on drug release from controlled drug delivery systems. Act Polori Pharmaceutic. 2010;67(3):217-223
  15. 15. Saganuwan SA. Comparatives therapeutic index, lethal time and safety margin of various toxicants and snake antivenins using newly derived and old formulas. BMC Research Notes. 2020;13(292):1-7
  16. 16. Saganuwan SA. The paradox of human equivalent dose formula: A canonical case study of Abrus Precatorius aqueous leaf extract in monogastric animals. Macedonian Veterinary Review. 2016;39(1):23-32
  17. 17. Renkin EM. Transport of potassium −42 from blood to tissue in isolated mammalian skeletal muscles. American Journal of Physiology. 1959;197(6):1205-1210
  18. 18. Crone C. The permeability of capillaries in various organs as determined by use of the indicator diffusion method. Acta Physiologica. 1963;58(4):292-305
  19. 19. Calvetti D, Cheng Y, Somersalo E. A spatial distributed computational model of brain cellular metabolism. Journal of Theoretical Biology. 2015;376:48-65
  20. 20. Karbowski J. Scaling of brain metabolism and blood flow in relation to capillary and neural scaling. PLoS One. 2011;6:e26709
  21. 21. Wong AD, Ye M, Levy AF, Rothstein JD, Bergles JD, Searson PC. The blood-brain barrier: An engineering perspective. Frontiers in Neuroengergy. 2013;6(7):1-22
  22. 22. Zlokovic BV. Neuromuscular mechanisms of Alzheimer’s neurodegeneration. Trends in Neurosciences. 2005;28:202-208
  23. 23. Ball K. A physiologically based modelling strategy during preclinical CNS drug development. Molecular Pharmaceutics. 2014;11:836-848
  24. 24. Yamamoh Y, Valitalo PA, Huntjens DR, Proost JH, Vermenlen A, Krauwinkel W, et al. Predicting drug concentration – Time profiles in multiple CNS compartments using a comprehensive physiologically –based pharmacokinetic model. CPT Pharmacemetrics and System Pharmacology. 2017;6(11):765-777
  25. 25. Yamamoto Y, Valitalo PA, van den Berg DJ, Hertran R, van den Brink W, Wong YC, et al. A generic multi-compartmental CNS distribution model structure for 9 drugs allows prediction of human brain target site concentrations. Pharmaceutical Research. 2017;34(2):333-351
  26. 26. Westerhout J, van den Berg DJ, Hartman R, Danhot M, De Lange ECM. Prediction of methotrexate CNS distribution in different species – Influence of disease conditions. European Journal of Pharmaceutical Sciences. 2014;57(1):11-24
  27. 27. Syvanen S, Xie R, Sahin S, Hammarhind-Udenaes M. Pharmacokinetic consequences of active drug efflux at the blood-brain barrier. Pharmaceutical Research. 2006;23(4):705-7147
  28. 28. Nhan T, Burgesb A, Lilge L, Hynynen K. Modelling localized delivery of doxorubicin to the brain following focused ultrasound enhanced blood-brain barrier permeability. Physics Medical Biology. 2014;59:5987-6004
  29. 29. Lai WQ, Chang YF, Chou FN, Yang DM. Protable FRET- based biosensor device for on-site lead detection. Bios. 2022;12(157):1-17
  30. 30. Nicholson C, Chen KC, Hrabetova S, Tao L. Diffusion of molecules in brain bitracellular space: Theory and experiment. Brain Research. 2000;125:129-154
  31. 31. Saltzman WM, Radiomsky ML. Drugs released from polymers: Diffusion and elimination in brain tissue. Chemical Engineering Science. 1991;46(10):2429-2444
  32. 32. Vendel E, Rottschafer V, de Lange ECM. The new for mathematical modelling of spatial drug distribution within the brain. Fluid Barrier CNS. 2019;16(12):1-33
  33. 33. Saganuwan SA. Mathematical determination of some oncological parameters and their therapeutic implications in dogs. Composite Clinical Pathology. 2019;28:1025-1030
  34. 34. Saganuwan SA. Modified formulas for calculation of encephalization quotient in dogs. BMC Research. 2021;14(223):1-5
  35. 35. Nicholson C. Diffusion and related transport mechanisms in brain tissue. Reports on Progress in Physics. 2001;64:815-884
  36. 36. Barbosa F Jr, Taruis-Santos JV, Gerlach RF, Parsons PJ. A critical review of biomarkers used for monitoring human exposure to lead: Advantages, limitations, and future needs. Environmental Health Perspectives. 2005;113:1569-1174
  37. 37. Wani AL, Ara A, Usman JA. Lead toxicity: A review. Interdisciplinary Toxicology. 2015;8(2):55-64
  38. 38. Saha A, Yakovlev VV. Applied Physics Letters. 2009;95:143704-143706
  39. 39. Rossi E. Clinical Biochemistry. 2008;29:63-70
  40. 40. He XM, Carter DC. Nature. 1992;358:209-215
  41. 41. Yuan Y, Cai Y, Xie Q, Yao S. Analytical Sciences. 2002;18:967-771
  42. 42. Peng L, Hongyu X, Xi L, Lifang R, Chaocan Z. Biological Trace Element Research. 2007;118:97-103
  43. 43. Ruckart PZ, Jones RL, Courtney JG, LeBlanc TT, Jackson W, Karwowski MP, et al. Update of the blood leads reference value-United States, 2021. Morbidity and Mortality Weekly Report. 2021;70(43):1509-1512
  44. 44. Goldstein GW. Lead poisoning and brain cell function. Environmental Health and Protection, Brogan and Partners Available from: http://www.jstor.org/stable/3430903. [Accessed: June 17, 2014]
  45. 45. Markovac J, Goldstein GW. Picomolar concentrations of lead stimulate brain protein kinase C. Nature. 1988;334:71-73
  46. 46. Gebhart AM, Goldstein GW. Use of an in-vitro system to study the effects of lead on astrocyte-endothelial cell interactions: A model for studying toxic injury to the blood-brain barrier. Toxicology and Applied Pharmacology. 1988;94:191-206
  47. 47. Lidsky TI, Schneider JS. Lead neurotoxicity in children: Basic mechanisms and clinical correlates. Brain. 2003;126:5-19
  48. 48. Navarrete A, van Schaik CP, Isler K. Energetics and the evolution of human brain size. Nature. 2011;480:91-93
  49. 49. Heinzer S, Kahn G, Krucker T, Meyer E, Ulmann-Schuler A. Novel three-dimensional analysis tool for vascular trees indicates complete micro-networks, not single capillaries, as the angiogaric and point in mice overexpressing human VEGF (65) in the brain. Neuroimag. 2008;39:1549-1558
  50. 50. Gross PM, Sposito NM, Pettersen SE, Fenstermacher JD. Differences in function and structure of the capillary endothelium in gray matter, white matter and circumventricular organ of rat brain. Blood Vessels. 1986;23:261-270
  51. 51. Potts R. Evolution big brains explained. Nature. 2011;480:43-44
  52. 52. Fang CW, Nimy HC, Huang YC, Chiang YS, Chuang CW, Wang IK, et al. Trend in blood lead levels in Taiwanese adults 2005 – 2007. PLoS One. 2021;16(12):e0260744
  53. 53. Chiang HC, Chang PY. Lead exposure among Kaosiung traffic policemen. Gaoxiong Yi Xueke Xue Zazhi. 1989;5(6):314-319
  54. 54. Deane R, Bradbury NWB. Transport of Lead – 203 at the Blood-Brain Barrier during Short Cerebrovascular Perfusion with Saline in the Rats. 1990
  55. 55. Frndak L, Barg G, Canfield RL, Quierolo EL, Manay N, Kordas K. Behavioural signatures of lead and manganese exposed children. Available from: https://www.sciencedirect.2022
  56. 56. Rocha A, Trujillo K. Neurotoxicity of low-level lead exposure: History, mechanisms of action, and behavioural effects in humans and prechemical models. Neurotoxicology. 2019;73:58-80
  57. 57. Kosnett MJ, Wedeen RP, Rothenberg SJ, Hipkins KL, Materna BL, Schwartz BS, et al. Recommendations for medical management of adult lead exposure. Environmental Health Perspectives. 2007;15(3):463-471
  58. 58. Hartman P, Ramsier A, Gudat F, Mihatsch MJ. Normal weight of the brain in adults in relation to age, sex, body height and weight. Der Pathologe. 1994;15(3):165-170
  59. 59. Miller AKH, Corsellis JAN. Evidence for a secular increase in human brain weight during the past century. Annals of Human Biology. 1973;4(3):253-257
  60. 60. Herculano-Houzel S. The human brain numbers: A linearly scaled-up primate brain. Frontiers in Human Neuroscience. 2009;3(31):1-11
  61. 61. Beason-Held LL, Horwitz B. Aging brain. In: Encyclopedia of the Human Brain. Amsterdam, Netherlands: Elsevier Science Limited; 2002
  62. 62. Paulson JA, Brown MJ. The CDC blood lead reference value for children: Time for a change. Environmental Health. 2019;18(16):1-2
  63. 63. Albo DM. Cognitive inferences in fossil apes (Primates, Hominoidea):Does encephalization reflect intelligence? Journal of Anthropological Sciences. 2010;88:11-48
  64. 64. Cairo O. External measures of cognition. Frontiers in Human Neuroscience. 2011;5(108):1-9
  65. 65. van Schaik CP, Triki Z, Bshary R, Heldstab SA. A farewell to the encephalization quotient: A new brain size measure for comparative primate cognition. Brain Behaviour and Evolution. 2021;96:1-12
  66. 66. Worthy GA, Hickie JP. Relative brain size in marine mammals. American Nature. 1986;128:445-459

Written By

Saganuwan Alhaji Saganuwan

Submitted: 03 June 2022 Reviewed: 29 August 2022 Published: 10 October 2022